1
|
Di Lorenzo G, Michele A, Silvana L, Bilancia D, Di Trolio R, Iuliucci MR, Ingenito C, Rubino R, Piscosquito A, Caraglia M, Donnarumma M, Costabile F, Conca R, Pisino M, Vaia A, Scafuri L, Verde A, Buonerba C. A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario. Oncol Ther 2024; 12:147-155. [PMID: 38112965 PMCID: PMC10881452 DOI: 10.1007/s40487-023-00256-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Accepted: 12/01/2023] [Indexed: 12/21/2023] Open
Abstract
INTRODUCTION This retrospective study investigates the efficacy of cemiplimab, a monoclonal antibody targeting the PD-1 receptor, in treating squamous cell carcinoma (SCC) of the skin. METHODS The study analyzes data from 50 patients with SCC, focusing on various clinical parameters, including patient demographics, tumor characteristics, treatment history, disease status at the beginning of therapy, and survival outcomes. RESULTS Of the patients who received at least one cycle of cemiplimab, 42% showed a clinical response. Adverse reactions were generally low, with the safety profile deemed excellent. During a median follow-up of 9.6 months, 17 patients experienced progression or death. Among these, 15 patients had died at the time of the analysis. The median progression-free survival (PFS) for the entire cohort was approximately 20.8 months, while median overall survival (OS) was not reached. Univariate Cox regression analysis for PFS showed that tumors in the arms and legs were associated with higher progression risk, while age above 65 years was not statistically significant. Distant metastasis exhibited a trend towards improved PFS. In terms of OS, distant metastasis was a significant predictor of reduced survival, while age above 65 years was not statistically significant. In a multivariate model, only the absence of distant metastasis remained significant, with an adjusted odds ratio (OR) of 12.3 (95% confidence interval 1.3-112.1). CONCLUSION These findings provide valuable insights into the real-world effectiveness of cemiplimab in SCC management.
Collapse
Affiliation(s)
- Giuseppe Di Lorenzo
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy.
- Associazione O.R.A. ETS, Salerno, Italy.
- Department of Medicine and Health Science, University of Molise, Campobasso, Italy.
| | - Aieta Michele
- Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy
| | - Leo Silvana
- Medical Oncology, 'Vito Fazzi' Hospital, Lecce, Italy
| | | | - Rossella Di Trolio
- Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples, Italy
| | | | - Concetta Ingenito
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
| | - Roberta Rubino
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
| | | | - Michele Caraglia
- Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy
- Laboratory of Precision and Molecular Oncology, Institute of Genetic Research, Biogem Scarl, Ariano Irpino, Avellino, Italy
| | | | - Ferdinando Costabile
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
- Associazione O.R.A. ETS, Salerno, Italy
| | - Raffaele Conca
- Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy
| | - Marco Pisino
- Medical Oncology, 'Vito Fazzi' Hospital, Lecce, Italy
| | - Angelo Vaia
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
- Ospedale San Carlo, Potenza, Italy
| | - Luca Scafuri
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
- Associazione O.R.A. ETS, Salerno, Italy
| | - Antonio Verde
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
- Associazione O.R.A. ETS, Salerno, Italy
| | - Carlo Buonerba
- Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy
- Associazione O.R.A. ETS, Salerno, Italy
- Department of Public Health, University Federico II of Naples, Naples, Italy
| |
Collapse
|